MiR-204 acts as a potential therapeutic target in acute myeloid leukemia by increasing BIRC6-mediated apoptosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Acute myeloid leukemia (AML) is one of the most common hematological malignancies all around the world. MicroRNAs have been determined to contribute various cancers initiation and progression, including AML. Although microRNA-204 (miR-204) exerts anti-tumor effects in several kinds of cancers, its function in AML remains unknown. In the present study, we assessed miR-204 expression in AML blood samples and cell lines. We also investigated the effects of miR-204 on cellular function of AML cells and the underlying mechanisms of the action of miR-204. Our results showed that miR-204 expression was significantly downregulated in AML tissues and cell lines. In addition, overexpression of miR-204 induced growth inhibition and apoptosis in AML cells, including AML5, HL-60, Kasumi-1 and U937 cells. Cell cycle analysis further confirmed an augmentation in theapoptotic subG1 population by miR-204 overexpression. Mechanistically, baculoviral inhibition of apoptosis protein repeat containing 6 (BIRC6) was identified as a direct target of miR-204. Enforcing miR-204 expression increased the luciferase activity and expression of BIRC6, as well as p53 and Bax expression. Moreover, restoration of BIRC6 reversed the pro-apoptotic effects of miR-204 overexpression in AML cells. Taken together, this study demonstrates that miR-204 causes AML cell apoptosis by targeting BIRC6, suggesting miR-204 may play an anti-carcinogenic role in AML and function as a novel biomarker and therapeutic target for the treatment of this disease.
Abstract
Acute myeloid leukemia (AML) is one of the most common hematological malignancies all around the world. MicroRNAs have been determined to contribute various cancers initiation and progression, including AML. Although microRNA-204 (miR-204) exerts anti-tumor effects in several kinds of cancers, its function in AML remains unknown. In the present study, we assessed miR-204 expression in AML blood samples and cell lines. We also investigated the effects of miR-204 on cellular function of AML cells and the underlying mechanisms of the action of miR-204. Our results showed that miR-204 expression was significantly downregulated in AML tissues and cell lines. In addition, overexpression of miR-204 induced growth inhibition and apoptosis in AML cells, including AML5, HL-60, Kasumi-1 and U937 cells. Cell cycle analysis further confirmed an augmentation in theapoptotic subG1 population by miR-204 overexpression. Mechanistically, baculoviral inhibition of apoptosis protein repeat containing 6 (BIRC6) was identified as a direct target of miR-204. Enforcing miR-204 expression increased the luciferase activity and expression of BIRC6, as well as p53 and Bax expression. Moreover, restoration of BIRC6 reversed the pro-apoptotic effects of miR-204 overexpression in AML cells. Taken together, this study demonstrates that miR-204 causes AML cell apoptosis by targeting BIRC6, suggesting miR-204 may play an anti-carcinogenic role in AML and function as a novel biomarker and therapeutic target for the treatment of this disease.
참고문헌 (27)
- Fulda S, "Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities", Leukemia, 28, pp.1414~1422 (2014)[DOI]
- Chen Z, "A human IAP-family gene, apollon, expressed in human brain cancer cells", Biochem Biophys Res Commun, 264, pp.847~854 (1999)[DOI]
- Martin SJ, "An Apollon vista of death and destruction", Nat Cell Biol, 6, pp.804~806 (2004)[DOI]
- Ismail EA, "BIRC6", Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis, 2012, pp.88, 118~127
- Sung KW, "Overexpression of Apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia", Clin Cancer Res, 13, pp.5109~5114 (2007)[DOI]
- Lopergolo A, "Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation", Br J Cancer, 100, pp.739~746 (2009)[DOI]
- Tang W, "BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation", Int J Cancer, 136, pp.E475~E487 (2015)[DOI]
- Shrestha S, "Integrated MicroRNA-mRNA Analysis Reveals miR-204 Inhibits Cell Proliferation in Gastric Cancer by Targeting CKS1B, CXCL1 and GPRC5A", Int J Mol Sci, 19 (2017)
- Shu Y, "MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1", p53 pathway, 2017, pp.8, 97313~97322
- Song CJ, "The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies", J Cell Biochem, 119, pp.2763~2786 (2017)
- Zhu X, "IL-6R", STAT3, Oncotarget, pp.2017, 8[DOI]
- Yin Y, "miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A", Clin Cancer Res, 20, pp.6187~6199 (2014)[DOI]
- Duan S, "MiR-204 Regulates Cell Proliferation and Invasion by Targeting EphB2 in Human Cervical Cancer", Oncol Res, 26, pp.713~723 (2017)
- Diaz-Martinez M, "miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma", Cancer Res, 78, pp.1017~1030 (2017)
- Luo YH, "Promising significance of the association of miR-204-5p expression with clinicopathological features of hepatocellular carcinoma", Medicine (Baltimore), 96, pp.e7545~ (2017)[DOI]
- Reubold TF, "A molecular view on signal transduction by the apoptosome", Cell Signal, 24, pp.1420~1425 (2012)[DOI]
- Li T, "The dual regulatory role of miR-204 in cancer", Tumour Biol, 37, pp.11667~11677 (2016)[DOI]
- Roldo C, "MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior", J Clin Oncol, 24, pp.4677~4684 (2006)[DOI]
- Zanette DL, "miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia", Braz J Med Biol Res, 40, pp.1435~1440 (2007)[DOI]
- Jin Z, "Overview of cell death signaling pathways", Cancer Biol Ther, 4, pp.139~163 (2005)
- Chu L, "Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil", Gene Ther, 15, pp.484~494 (2008)[DOI]
- Choi H, "Epstein-Barr virus-encoded microRNA BART15-3p promotes cell apoptosis partially by targeting BRUCE", J Virol, 87, pp.8135~8144 (2013)[DOI]
- Crippa E, "miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells", Oncotarget, 7, pp.18594~18604 (2016)
- Druz A, "A novel microRNA mmu-miR-466h affects apoptosis regulation in mammalian cells", Biotechnol Bioeng, 108, pp.1651~1661 (2011)[DOI]
- Van Houdt WJ, "Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target", Mol Cell Proteomics, 10, pp.M111 011353~ (2011)[DOI]
- Bartke T, "Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2", E3 ubiquitin ligase, 2004, pp.14, 801~811
- Okumu DO, "BIRC6 mediates imatinib resistance independently of Mcl-1", PLoS One, 12, pp.e0177871~ (2017)[DOI]